Income Statement
ARRIVENT BIOPHARMA, INC.
AVBP
Performance Overview
Click any row in the table to add it to this chart
in millions USD
| Metric | Dec 31, 2025 2025 FY | Dec 31, 2024 2024 FY |
|---|---|---|
|
Revenue
|
- | - |
|
Cost of Revenue
|
- | - |
|
Gross Profit
|
- | - |
|
Operating Expenses
|
177.53 | 94.31 |
|
Research & Development
|
153.35 | 79.00 |
|
Selling, General & Administrative
|
24.18 | 15.30 |
|
Other Operating Expenses
|
- | - |
|
Operating Income
|
-177.53 | -94.31 |
|
Non-Operating Income
|
- | - |
|
Interest Income
|
- | - |
|
Interest Expense
|
- | - |
|
Other Non-Op Income / Expense
|
- | - |
|
Income Before Tax
|
- | - |
|
Income Tax Expense
|
- | - |
|
Non-Controlling Interest
|
- | - |
|
Net Income
|
-166.31 | -80.49 |
Supplemental
Per share data, derived & other items — not part of the income statement
in millions USD unless noted
| Metric | Dec 31, 2025 2025 FY | Dec 31, 2024 2024 FY |
|---|---|---|
|
Depreciation & Amortization
|
- | - |
|
EBITDA
|
-177.53 | -94.31 |
|
Earnings Per Share (Basic)
|
-4.32 | -2.56 |
|
Diluted EPS
|
-4.32 | -2.56 |
|
Weighted Average Shares
|
38.46 | 31.47 |
|
Diluted Weighted Avg Shares
|
38.46 | 31.47 |
|
Comprehensive Income
|
-166.08 | -80.70 |